Recital 10, Regulation (EU) 2024/425

In forcesince 2 Feb 2024

As regards the new criteria to identify endocrine disrupting properties introduced by Commission Regulation (EU) 2018/605 [Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out scientific criteria for the determination of endocrine disrupting properties. (OJ L 101, 20.4.2018, p. 33).], which became applicable on 10 November 2018, the conclusion of the Authority did not allow risk managers to conclude whether the active substance asulam-sodium is an endocrine disruptor, as the conclusion was completed before these new criteria entered into force. Therefore, in February 2019 the Commission requested the Authority to re-assess the information and update its conclusion on the potential endocrine disruption properties of asulam-sodium in accordance with the new criteria. as set out in point 3.6.5 of Annex II to Regulation (EC) No 1107/2009.